Opiant Pharmaceuticals Overview

  • Status
  • Public

  • Employees
  • 37

Employees
  • Stock Symbol
  • OPNT

Stock Symbol
  • Share Price
  • $13.48

  • (As of Friday Closing)

Opiant Pharmaceuticals General Information

Description

Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.

Contact Information

Website
www.opiant.com
Formerly Known As
Lightlake Therapeutics, Madrona Ventures
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Stock Exchange
NAS
Primary Office
  • 233 Wilshire Boulevard
  • Suite 280
  • Santa Monica, CA 90401
  • United States
+1 (310) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Opiant Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$13.48 $12.58 $7.34 - $37.71 $64M 5.16M 36.6K -$1.11

Opiant Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 72,802 128,323 3,490 36,592
Revenue 38,585 40,725 27,402 38,236
EBITDA (3,673) 5,812 (1,642) 11,216
Net Income (6,335) 3,009 (1,861) 11,593
Total Assets 60,319 70,428 60,613 40,281
Total Debt 14,551 17,080 18,983 772
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Opiant Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Opiant Pharmaceuticals‘s full profile, request access.

Request a free trial

Opiant Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatm
Drug Discovery
Santa Monica, CA
37 As of 2021
00.000
000000000 00.000

00000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptat
0000000000000
South San Francisco, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Opiant Pharmaceuticals Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000 000000000000 Corporation South San Francisco, CA 00 00000 000000000 00000
You’re viewing 1 of 1 competitors. Get the full list »

Opiant Pharmaceuticals Patents

Opiant Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210015791-A1 Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist Pending 18-Jun-2019 0000000000
EP-3986856-A1 Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist Pending 18-Jun-2019 0000000000
AU-2020296012-A1 Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist Pending 18-Jun-2019 0000000000
US-20200397749-A1 Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist Pending 18-Jun-2019 000000000
US-20200390691-A1 Compositions, devices, and methods for the treatment of overdose and reward-based disorders Pending 20-Dec-2018 A61K31/485
To view Opiant Pharmaceuticals’s complete patent history, request access »

Opiant Pharmaceuticals Executive Team (11)

Name Title Board Seat Contact Info
Roger Crystal MD Chief Executive Officer & Board Member
David O'Toole Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Mark Ellison Ph.D Chief Development Officer
Phil Skolnick Ph.D Chief Scientific Officer
Marie Brown Executive Director, Marketing
You’re viewing 5 of 11 executive team members. Get the full list »

Opiant Pharmaceuticals Board Members (6)

Name Representing Role Since
00000 0000000 Self Chairman & Board Member 000 0000
000000000 000000 00 Self Board Member 000 0000
00000000 0000000 00 Opiant Pharmaceuticals Board Member 000 0000
0000000 00000000 Opiant Pharmaceuticals Board Member 000 0000
0000000 0000 Opiant Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Opiant Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial